OTLK Key Statistics, Chart & Performance
The current stock price of OTLK is 0.6043 USD. In the past month the price decreased by -70.95%. In the past year, price decreased by -74.5%.
OTLK Latest News, Press Relases and Analysis
OTLK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.72 | 396.12B | ||
| AMGN | AMGEN INC | 15.09 | 177.76B | ||
| GILD | GILEAD SCIENCES INC | 14.73 | 149.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.06 | 119.17B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.8 | 84.19B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 783.14 | 52.76B | ||
| INSM | INSMED INC | N/A | 36.31B | ||
| NTRA | NATERA INC | N/A | 33.06B | ||
| BIIB | BIOGEN INC | 11.11 | 27.29B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.6 | 21.14B | ||
| INCY | INCYTE CORP | 16.5 | 20.79B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.76B |
Related stock screener links
About OTLK
Company Profile
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. The company is headquartered in Iselin, New Jersey and currently employs 23 full-time employees. The company went IPO on 2016-06-13. The firm is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. The company is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Company Info
OUTLOOK THERAPEUTICS INC
111 S. Wood Avenue, Unit #100
Iselin NEW JERSEY 08852 US
CEO: Lawrence A. Kenyon
Employees: 23
Phone: 16096193990
OUTLOOK THERAPEUTICS INC / OTLK FAQ
What does OUTLOOK THERAPEUTICS INC do?
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. The company is headquartered in Iselin, New Jersey and currently employs 23 full-time employees. The company went IPO on 2016-06-13. The firm is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. The company is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Can you provide the latest stock price for OUTLOOK THERAPEUTICS INC?
The current stock price of OTLK is 0.6043 USD. The price increased by 2.42% in the last trading session.
Does OUTLOOK THERAPEUTICS INC pay dividends?
OTLK does not pay a dividend.
What is the ChartMill technical and fundamental rating of OTLK stock?
OTLK has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Should I buy OTLK stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on OTLK.
Can you provide the growth outlook for OUTLOOK THERAPEUTICS INC?
The Revenue of OUTLOOK THERAPEUTICS INC (OTLK) is expected to grow by 343.11% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the upcoming earnings date for OUTLOOK THERAPEUTICS INC?
OUTLOOK THERAPEUTICS INC (OTLK) will report earnings on 2026-02-12.
OTLK Technical Analysis
OTLK Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to OTLK. OTLK has a bad profitability rating. Also its financial health evaluation is rather negative.
OTLK Financial Highlights
Over the last trailing twelve months OTLK reported a non-GAAP Earnings per Share(EPS) of -0.42. The EPS increased by 82.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -194.01% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
OTLK Forecast & Estimates
11 analysts have analysed OTLK and the average price target is 9.69 USD. This implies a price increase of 1503.51% is expected in the next year compared to the current price of 0.6043.
For the next year, analysts expect an EPS growth of -135.57% and a revenue growth 343.11% for OTLK